J9340 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 J9340 summary

J9340 is a HCPCS Level II J-code used to bill thiotepa, 15 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9340: Tepadina(J9340)*, Thiotepa, Tepadina

Code J9340 NDC-Crosswalk 13 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9340

DescriptorInjection, thiotepa, 15 mg

Billing unitNot available in current dataset

Payment limit / unit Not available in current dataset

Mapped NDCs13

Data periodNot available in current dataset

Last updatedSource date not available

💊 About Thiotepa Injection DRUG GUIDE

Tepadina (thiotepa) injection is used for several purposes.

It treats adenocarcinoma (a type of cancer) of the breast or ovary.

It is also used to control malignant effusions — abnormal fluid buildup in body cavities caused by cancer spreading to those areas.

For bladder cancer, Tepadina treats superficial papillary carcinoma of the urinary bladder.Tepadina is also used in pediatric patients with class 3 beta-thalassemia (a severe inherited blood disorder).

Read the full Thiotepa Injection drug guide →

Clinical overview from our editorial drug guide for Thiotepa Injection. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS

Medicare payment limit / unit

—

Est. ASP / unit

—

Est. after 2% sequester

—

HCPCS dosage

—

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly).

Full HCPCS code details (official CMS record)

Long descriptionInjection, thiotepa, 15 mg

CoverageD — Special coverage instructions apply

Pricing indicator51 — Drug — priced under the ASP methodology

Type of service1 — Medical care

BETOS-2O1D

ASC payment groupYY

Action codeN — No maintenance this year

Effective date2009-01-01

Date added1984-01-01

Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9340 = 1 unit. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (unit) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9340 CROSSWALKED NDCs

13 NDCs map to J9340. Bill units = how many HCPCS units one package represents.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	NADAC / unit	Status	Source
00143-9292-01	Thiotepa 100 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Hikma	1 VIAL in 1 BOX, UNIT-DOSE (0143-9292-01)...	100 mg/1	6.667	—	● Active	PDAC
71288-0156-05	Thiotepa 15 mg/1 INJECTION, POWDER, FOR SOLUTION	Meitheal	1 VIAL, SINGLE-DOSE in 1 CARTON (71288-156...	15 mg/1	1	—	● Active	PDAC
71288-0157-10	Thiotepa 100 mg/1 INJECTION, POWDER, FOR SOLUTION	Meitheal	1 VIAL, SINGLE-DOSE in 1 CARTON (71288-157...	100 mg/1	6.667	—	● Active	PDAC
65219-0029-20	Thiotepa 100 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Fresenius	1 VIAL in 1 CARTON (65219-029-20) / 1 INJ...	100 mg/1	6.667	—	● Active	PDAC
72205-0045-01	Thiotepa 15 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Novadoz	1 VIAL, GLASS in 1 BOX (72205-045-01) / 1...	15 mg/1	1	—	● Active	PDAC
72205-0046-01	Thiotepa 100 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Novadoz	1 VIAL, GLASS in 1 BOX (72205-046-01) / 1...	100 mg/1	6.667	—	● Active	PDAC
00143-9309-01	Thiotepa 15 mg/1.5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Hikma	1 VIAL in 1 BOX, UNIT-DOSE (0143-9309-01)...	15 mg/1.5mL	1	—	● Active	PDAC
43598-0650-11	Thiotepa 15 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Dr.Reddy's	1 VIAL in 1 CARTON (43598-650-11) / 1 INJ...	15 mg/1	1	—	● Active	PDAC
70121-1630-01	TEPADINA THIOTEPA 15 mg/1 INJECTION, POWDER, FOR SOLUTION	Amneal	1 VIAL, GLASS in 1 BOX (70121-1630-1) / 1...	15 mg/1	1	—	● Active	PDAC
70121-1631-01	TEPADINA THIOTEPA 100 mg/1 INJECTION, POWDER, FOR SOLUTION	Amneal	1 VIAL, GLASS in 1 BOX (70121-1631-1) / 1...	100 mg/1	6.667	—	● Active	PDAC
53964-0001-01	TEPADINA 15 MG	Unknown	—	—	1	—	—	PDAC
53964-0002-02	TEPADINA 100 MG	Unknown	—	—	6.667	—	—	PDAC
00143-9565-01	Thiotepa 15 mg/1.5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	Hikma	1 VIAL in 1 BOX, UNIT-DOSE (0143-9565-01)...	15 mg/1.5mL	1	—	● Active	PDAC

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse J9340 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with J9340. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from J9340
J9342	THIOTEPA*	1 MG	$4.931	Related ingredient or formulation — confirm strength, form and billing unit before substituting.

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend

$46.3K

Claims

56

Beneficiaries

21

Spend / beneficiary

$2,204.16

Spend / claim

$826.56

Where J9340 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5

Total spending — #738 of 918

#733 LACTATED RINGERS J7120 $48.9K #734 FIRAZYR* J1744 $48.5K #735 SIVEXTRO J3090 $48.4K #736 MORPHINE SULFATE(J22... J2270 $47.1K #737 STEQEYMA Q5099 $46.5K #738 TEPADINA(J9340)* J9340 $46.3K #739 ZYPREXA RELPREVV J2358 $46.3K #740 ORPHENADRINE CITRATE J2360 $45.9K #741 DIPYRIDAMOLE J1245 $45K #742 XERAVA J0122 $43.5K #743 DEXTROSE IN WATER(J7... J7060 $42.3K

Total claims — #839 of 918

#834 AMNIOCORE PER SQ CM*... Q4227 63 #835 ABECMA Q2055 61 #836 BIOVANCE 1 SQUARE CM... Q4154 57 #837 FRAGMIN J1645 56 #838 ARIXTRA* J1652 56 #839 TEPADINA(J9340)* J9340 56 #840 TEPADINA(J9342)* J9342 54 #841 DEXAMETHASONE INTENS... J8540 53 #842 CANCIDAS* J0637 52 #843 IXINITY J7213 52 #844 ZEVTERA J0681 51

Full breakdown by period (1)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2025 (Q1-Q4)	$46.3K	21	56	$2,204.16	$826.56

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.

Allowed charges

—

Medicare paid

$1.9K

Submitted services

—

Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J9340 is utilized

⏳

The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J9340

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient

Thiotepa 9

THIOTEPA 2

NDC products by labeler

Hikma Pharmaceuticals USA Inc. 3

Amneal Pharmaceuticals LLC 2

Meitheal Pharmaceuticals Inc 2

Novadoz Pharmaceuticals LLC 2

Dr.Reddy's Laboratories Inc., 1

Fresenius Kabi USA, LLC 1

🔗 Related NDC directory pages

🧪 All Thiotepa NDCsIngredient 🧪 All Thiotepa NDCsIngredient 🏭 All Hikma labeler NDCsLabeler 00143 🏭 All Amneal labeler NDCsLabeler 70121 🏭 All Meitheal labeler NDCsLabeler 71288 🏭 All Novadoz labeler NDCsLabeler 72205 📚 All Alkylating Drug NDCsDrug class

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Loaded

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Not available

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)

13 NDCs mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2025

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9340 billing FAQ

What is HCPCS code J9340?

J9340 is a HCPCS Level II J-code used to bill Injection, thiotepa, 15 mg under Medicare Part B and most medical (not pharmacy) benefits.

Which NDCs bill under J9340?

13 NDCs currently map to J9340 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean J9340 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

J9340 – Injection, thiotepa, 15 mg · NDC Crosswalk & Billing Units